Subcellular Compartmentalization of Activation and Desensitization of Responses Mediated by NK2 Neurokinin Receptors

Jean-Yves Vollmer, Philippe Alix, André Chollet, Kenneth Takeda, Jean-Luc Galzi

To cite this version:
Jean-Yves Vollmer, Philippe Alix, André Chollet, Kenneth Takeda, Jean-Luc Galzi. Subcellular Compartmentalization of Activation and Desensitization of Responses Mediated by NK2 Neurokinin Receptors. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 1999, 274, pp.37915 - 37922. 10.1074/jbc.274.53.37915 . hal-02194199

HAL Id: hal-02194199
https://hal.archives-ouvertes.fr/hal-02194199
Submitted on 25 Jul 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Subcellular Compartmentalization of Activation and Desensitization of Responses Mediated by NK2 Neurokinin Receptors*

(Received for publication, August 9, 1999, and in revised form, September 24, 1999)

Jean-Yves Vollmer§§, Philippe Alix¶¶, André Chollet, Kenneth Takeda**, and Jean-Luc Galzi§§§

From the §Département Recepteurs et Protéines Membranaires, CNRS UPR 9050, École Supérieure de Biotechnologie de Strasbourg, Boulevard Sébastien Brant, 67400 Illkirch, France, ¶¶Serono Pharmaceutical Research Institute, 14 chemin des Auxx, CH-1228 Plan-les-Ouates/Gè涅ve, Switzerland, and **Pharmacologie et Physiologie des Interactions Cellulaires et Moléculaires, CNRS UMR 7034, Université Louis Pasteur de Strasbourg, Faculté de Pharmacie, B.P. 24, 67401 Illkirch, France

A functional fluorescent neurokinin NK2 receptor was constructed by joining enhanced green fluorescent protein to the amino-terminal end of the rat NK2 receptor and was expressed in human embryonic kidney cells. On cell suspensions, the binding of fluorescent Bodipy-labeled neurokinin A results in a saturable and reversible decrease of NK2 receptor fluorescence via fluorescence resonance energy transfer. This can be quantified for nM to μM agonist concentrations and monitored in parallel with intracellular calcium responses. On single cells, receptor site occupancy and local agonist concentration can be determined in real time from the decrease in receptor fluorescence. Simultaneous measurement of intracellular calcium responses and agonist binding reveals that partial receptor site occupancy is sufficient to desensitize cellular response to a second agonist application to the same membrane area. Subsequent stimulation of a distal membrane area leads to a second response to agonist, provided that it had not been exposed to agonist during the first application. Together with persistent translocation of fluorescent protein kinase C to the membrane area exposed to agonist, the present data support that not only homologous desensitization but also heterologous desensitization of NK2 receptors is compartmentalized to discrete membrane domains.

Neurotransmitters stimulate target cells upon interacting with two major categories of regulatory proteins, ligand-gated ion channels (1–3), and G protein-coupled receptors (4). For ligand-gated ion channels, response activation and termination are mediated by a single molecule that carries the neurotransmitter site and the effector site (1). In contrast, responses mediated by G protein-coupled receptors result from a complex cascade of transient and sequential interactions between the receptor and a series of distinct messengers and effector proteins, which belong to distinct subcellular compartments (5–9).

Tachykinins or neurokinins form a family of related neuropeptides found throughout central and peripheral nervous tissues. Their biological activities related to pain transmission (10, 11), smooth muscle contraction, vasodilation, or neurogenic inflammation are mediated by at least three distinct G protein-coupled receptors, NK1, NK2, and NK3, that show preferential binding for the endogenous agonists substance P, neurokinin A (NKA),1 and neurokinin B (NKB), respectively (12). All three receptor isoforms belong to the family of seven transmembrane regulatory proteins and are coupled to an intracellular calcium release response primarily mediated by the pertussis toxin-insensitive heterotrimeric GTP-binding protein Gq/G11.

In the present work, we have used fluorescence resonance energy transfer-based detection of neurokinin A binding to its G protein-coupled receptor, the NK2 tachykinin receptor, to detect real-time interactions on living cells and to study the spatial distribution of response activation and desensitization at the single cell level. Tachykinin NK2 receptors were fluorescently labeled at the amino-terminal end with EGFP and expressed as functional membrane-bound receptors in HEK 293 cells. The binding of the natural neuropeptide neurokinin A chemically labeled with the fluorophore Bodipy 530/550 can be monitored by fluorescence resonance energy transfer and quantified both on cell suspensions and single cells. Real time ligand binding with high spatial resolution was measured in single cells, thereby permitting investigation of the relationships between the distribution of receptor activation/desensitization and cellular responses.

EXPERIMENTAL PROCEDURES

cDNA Constructs, Expression, and Selection—Rat NK2R cDNA (56) was provided by Prof. S. Nakashiba (Kyoto University), α7-5HT3 cDNA (57) in KS vector was provided by Prof. J. P. Changeux (Institut Pasteur, Paris, France), PKCα-EGFP in pEGFP-C1 vector was obtained from Dr. D. Joubert (INSERM U469, Montpellier, France). The α7-5HT3 sequence was excised from the plasmid by the restriction enzymes BsrGI and XhoI leaving the α7 signal sequence (Nol-BsrGI fragment) linked to the KS vector. EGFβ (pEGFP-C3, CLONTECH) was mutated to introduce an additional BsrGI site (Sculptor site-directed mutagenesis kit, Amersham Pharmacia Biotech) on its translation initiation codon and cloned in frame with the signal sequence as a BsrGI-XhoI fragment (KS-sp-EGFP). NK2R cDNA in vector SK was subcloned in vector KS between the SpeI (5’-end) and XhoI (3’-end) sites. The large XhoI fragment was then cloned in the XhoI site of KS-sp-EGFP to yield chimera 1. Chimera 2 was obtained after introducing an XhoI site on nucleotide 99 of the NK2R coding sequence, to permit in frame fusion with EGFP. All constructs were then ligated in

1 The abbreviations used are: NKA and NKB, neurokinin A and B; Bo, Bodipy 530/550; EGFP, enhanced green fluorescent protein; sp, signal peptide; WT, wild type; PKC, protein kinase C.
the expression vector pCEP4 (Invitrogen) between the NotI and XhoI sites for expression in HEK 293 cells.

HEK 293 cells, grown in minimal essential medium supplemented with 10% fetal calf serum and antibiotics, were transfected by calcium phosphate precipitation (58) and selected with 500 or 400 μg/ml hygromycin B.

Radioligand Binding Experiments—All peptides used were obtained from Bachem. [3H]SR48968 (Amersham Pharmacia Biotech) binding was performed on intact cells (25,000 cells/50 μl) in Hepes buffer (137.5 mM NaCl, 1.25 mM MgCl₂, 1.25 mM CaCl₂, 6 mM KCl, 55 mM glucose, 10 mM Hepes, 0.4 mM NaH₂PO₄, 1% bovine serum albumin (w/v) supplemented with protease inhibitors (Complete, Roche Molecular Biochemicals) at 4 °C for 2 h. Samples were filtered through GF/C filters preincubated with 1% (w/v) milk powder in phosphate-buffered saline (137.5 mM NaCl, 2.68 mM KCl, 8.06 mM Na₂HPO₄, 1.47 mM KH₂PO₄) and rinsed twice with phosphate-buffered saline. Competition experiments were performed with 0.5–1 nM [3H]SR48968, and experimental IC₅₀ values were converted to Kᵣ values using the Cheng and Prusoff relation (59). SR48968 was kindly given by Dr. Endomits-Alt (60). For inhibition of [¹²⁵I]NKA binding experiments, Kᵣ values were determined by taking Kᵣ = 1 nM for NKA (14).

Synthesis of Fluorescent NKA—All reactants are dissolved in dimethylformamide. Neurokinin A (0.2 μmol) was mixed with 0.4 μmol of iodoacetyl-Bodipy 530/550 (Molecular Probes) and 0.8 μmol of triethylamine. The volume was adjusted to 100 μl with dimethylformamide, stirred, and allowed to stand at room temperature for 16 h. The reaction mixture was then applied to a reverse phase high pressure liquid chromatography column (Zorbax Z5C8 25F) equilibrated with 90% A (0.1% trifluoroacetic acid in H₂O) 10% solvent B (0.1% trifluoroacetic acid, 3% acetonitrile, 0.08% gromycin B, 0.1% trifluoroacetic acid in acetonitrile) and eluted at 1 ml/min using a 10–95% gradient of solvent B in 60 min. Elution was monitored by optical absorption at 219 and 350 nm. The product eluting at 34 min, which exhibits strong absorption at both wavelength, was collected, concentrated, and characterized as the mono-Bodipy 530/550 derivative of neurokinin A (designated NKA-Bo) by spectrofluorimetry and by electron-spray mass spectrometry (calculated molecular mass 1630 Daltons, determined 1629.55).

Fluorescence Measurements—All fluorescence measurements from cell suspensions were made on a Fluorolog (SPEX) spectrofluorimeter equipped with a 450 watt Xe lamp, a double grating excitation monochromator, and a single grating emission monochromator. Slits were set to 4 or 6 mm yielding bandwidths of 7.2 or 10.8 nm at excitation and 14.4 and 21.6 nm at emission. Data were acquired with a photon counting photomultiplier (linear up to 10⁶ counts/sec). Unless otherwise stated, cells were made on a Fluorolog (SPEX) spectrofluorimeter linked to the NK2 receptor are separated by 35–75 Å.

Responses Mediated by NK2 Neurokinin Receptors

RESULTS

Construction of Fluorescent Chimeric NK2 Receptors and Neurokinin A—Site-directed mutagenesis and ligand binding studies of NK2 tachykinin receptors (13, 14), as well as photoaffinity labeling of NK1 receptors using p-benzoyl-p-phenylalanine-substance P (15, 16), have provided strong support to the notion that tachykinins bind to extracellular domains of their respective receptor isotypes (17). To detect the interaction of neurokinin A with the NK2 receptor by fluorescence resonance energy transfer, we prepared two complementary DNA constructs joining the carboxyl terminus of EGF P to the hydrophilic amino-terminal part of the NK2 receptor at positions 15 (chimera 1) and 33 (chimera 2). As EGF P is not secreted by cells and according to the known extracellular localization of the amino-terminal end of G protein-coupled receptors, the amino-terminal end of EGF P was further fused to the first 31 residues of the nicotinic receptor α7 subunit (18) comprising a signal peptide to promote translocation of the amino-terminal domain to the extracellular space.

Neurokinin A was chemically derivatized by reaction of the amino group of its amino-terminal histidine residue with the fluorescent group Bodipy 530/550 iodoacetate, to yield a fluorescent mono-derivative, NKA-Bo. From the overlap between the absorbance spectrum of the Bodipy group and the emission spectrum of EGF P a theoretical Ro value of 52.6 Å was calculated. Energy transfer is thus expected to occur with more than 10% efficiency if the Bodipy group linked to NKA, and EGF P linked to the NK2 receptor are separated by 35–75 Å.

On transfection into HEK 293 cells, cDNAs encoding chimera 1 and 2 lead to the expression of fluorescent proteins exhibiting the characteristic excitation and emission spectra of EGF P. However, only chimera 1 yielded surface 125I-labeled neurokinin A binding sites sensitive to the competitive antagonist SR48968 (not shown) and was therefore used in further studies.

On confocal micrographs, chimera 1 decorates plasma membranes in HEK 293 cells (Fig. 1A). After incubation of the cells with 10 μM neurokinin A for 30 min at 37 °C, spots of intense fluorescence are detected at the plasma membrane, as well as on each confocal cross-section through the cell (Fig. 1B), strongly suggesting that receptor capping and internalization takes place after agonist exposure. On the other hand, preincubation with 10 μM of the competitive antagonist SR48968 results in a chimera 1 fluorescence distribution comparable to that of control (Fig. 1C).

Functional and Pharmacological Properties of Fluorescent Chimera 1—As shown in Fig. 1D, the addition of 10 nM NKA or 10 nM NKA-Bo to chimera 1 expressing HER 293 cells loaded with the calcium indicator Fura-2 results in a typical intracellular calcium elevation response. These responses were not detected from nontransfected cells and are blocked by preincubation with the NK2-selective nonpeptide antagonist SR48968 (1 μM; Fig. 1D) as well as by the peptide antagonists cyclo(Gln-Trp-Phe-Gly-Leu-Met) (5 μM) or MEn-10,376 (10 μM).

Equilibrium binding studies reveal that [³H]SR48968 interacts with saturable binding sites on cells expressing either
WT receptor or chimera 1 (Fig. 1E). Fusion of the NK2R with EGFP does not affect [3H]SR48968 affinity (WT, $K_d = 0.92 \pm 0.13 \text{ nM}$; chimera 1, $K_d = 0.98 \pm 0.17 \text{ nM}$) nor the number of chimera 1 sites ($B_{\text{max}} = 0.1 \text{ pmol/25,000 cells, about } 2 \times 10^6$ receptors expressed/cell) as compared with WT NK2 receptor ($B_{\text{max}} = 0.08 \text{ pmol/25,000 cells}$).

Inhibition of [3H]SR48968 binding to WT receptor and chimera 1 (Fig. 1F) by the agonist NKA (WT, $K_d = 64 \pm 10 \text{ nM}$; chimera 1, $K_d = 64 \pm 25 \text{ nM}$; n = 3) or by the antagonist peptide MEN-10,376 (WT, $K_i = 53 \pm 18 \text{ nM}$, n = 3; chimera 1, $K_i = 62 \pm 32 \text{ nM}$, n = 3; not shown) also indicates that fusion of EGFP to the NK2 receptor does not significantly alter its pharmacological properties. Inhibition of [3H]SR48968 binding to WT NK2R and chimera 1 by the fluorescent neurokinin A derivative, NKA-Bo, again reveals no difference between the two receptors (WT, $K_{\text{NKA-Bo}} = 19.0 \pm 3.5 \text{ nM}$; chimera 1, $K_{\text{NKA-Bo}} = 16.6 \pm 5.7 \text{ nM}$, n = 3, data not shown) and shows that NKA-Bo exhibits about 3-fold higher equilibrium affinity than NKA.

When tested for competition against [125I]NKA binding, both NKA and NKA-Bo exhibit higher apparent affinity (chimera 1, $K_d = 1.5 \pm 0.5 \text{ nM}$; chimera 1, $K_d = 1.0 \pm 0.7 \text{ nM}$) than when tested in competition against [3H]SR48968, as has been described on cells expressing WT NK2 receptors (14). Thus, both the fluorescent NK2 receptor and the fluorescent neurokinin A derivative exhibit pharmacological and functional properties practically identical to those of their unmodified counterparts and therefore validate attempts to detect their interaction via fluorescence resonance energy transfer.

Detection and quantification of receptor-ligand interactions by fluorescence resonance energy transfer on living cells—Fluorescence resonance energy transfer experiments were carried out by exciting a cell suspension at the EGFP excitation wavelength (460–470 nm) and measuring either reduction of EGFP emission (at 510 nm) or an increase of emission of the Bodipy group (at 550 nm) (Fig. 2A). As illustrated in Fig. 2B, the addition of 23 or 46 nM NKA-Bo to a suspension of 10^6 cells/ml expressing chimera 1 results in a progressive decrease in EGFP emission (at 510 nm) and a progressive increase in Bodipy emission (at 550 nm). Further addition of an excess of unlabeled NKA (10 μM), of SR48968 (20 μM), or of MEN-10,376 (20 μM) fully restores EGFP emission to its initial level and partially reduces emission at the wavelength of the Bodipy group (Fig. 2C).

To ascertain that the observed fluorescence changes are because of energy transfer, the excitation spectrum of the donor was recorded at the emission of the acceptor. Indeed, excitation spectra (410–530 nm) monitored at Bodipy emission (570 nm) in the presence of 23 nM NKA-Bo and in the presence of 23 nM NKA-Bo together with 10 μM SR48968 allowed the determination of a subtraction excitation spectrum (Fig. 2D), which superimposes well with the excitation spectrum of EGFP directly recorded at EGFP emission (550 nm) in the absence of any ligand. This experiment thus strongly supports that both reduction of EGFP emission and increase of NKA-Bo emission signals (Fig. 2C) are because of fluorescence resonance energy transfer.

Reduction of chimera 1 emission amplitude at 510 ± 22 nm is proportional to the concentration of added NKA-Bo. Fig. 3A shows that in a continuous recording mode, the amplitude of EGFP emission decrease reaches a plateau value for ligand concentrations beyond 60 nM. When excitation is set to 460 ± 11 nm, the maximal decrease of fluorescence is close to 30% of total fluorescence (Fig. 3A) for cells selected with 0.5 mg/ml hygromycin B. Maximal extinction was 40% when excitation was set to 470 ± 10 nm (Fig. 2C). A plot of chimera 1 emission amplitude changes versus NKA-Bo concentration (Fig. 3B) yields a binding curve that is best fit with a single category of sites (n_H = 1.0 ± 0.1) and an apparent $K_d$ value of 8.85 ± 1.02 nM (n = 8). This value is intermediate compared with the apparent affinities determined by competition against [3H] SR
48968 and $^{[125]}$I-NKA and presumably reflects binding of NKA-Bo to two conformations of the receptor. When NKA-Bo concentration is set to its apparent $K_D$ value, NKA and SR48968 inhibit NKA-Bo binding to chimera 1 (Fig. 3C) with apparent inhibition constant values of 27.7 $\pm$ 6.0 nM ($n = 5$) and 1.7 $\pm$ 0.1 nM ($n = 5$), respectively.

**Sensitivity of Ligand-Receptor Complex Detection**—Steady-state receptor-ligand interactions were typically monitored in a 1-ml cuvette with irradiation and observation windows (3 $\times$ 10 mm) such that the efficacious volume of the cell suspension was 90 $\mu$L. At a standard cell concentration ($10^6$ cells/ml), the fluorescence signal was thus statistically recorded from 90,000 cells. To test for detection sensitivity, the cell concentration was decreased to 250,000 and 100,000 cells/ml. Taking the lowest cell concentration (100,000 cells/ml) as reference, initial chimera 1 fluorescence was found to increase by 2-fold at 250,000 cells/ml and by 8-fold at 1,000,000 cells/ml, in agreement with the notion that the efficacious irradiated and recorded sample volume decreases because of light scattering. However, at all cell concentrations, the addition of 60 nM NKA-Bo caused a specific reversible 30% reduction of EGFP emission amplitude (excitation 460 $\pm$ 11 nm, data not shown). The interaction between chimera 1 and NKA-Bo can thus be recorded in a standard spectrofluorimeter from a minimum of about 10,000 cells and represents a fixed proportion of total fluorescence, thus allowing to determine the fraction of receptors occupied independently of cell concentration.

**Single Cell Recording of Ligand Binding and Intracellular**
Calcium Elevation—Observation of single cell fluorescence by confocal microscopy reveals that NKA-Bo application results in a decrease of receptor fluorescence in a reversible manner (Fig. 4). This reduction exhibits dose dependence with NKA-Bo concentration and does not occur when an excess of SR48968 is applied together with fluorescent agonist (not shown). As observed on cell suspensions, saturating concentrations of fluorescent agonist (200 nM-2 μM) lead to a maximal fluorescence extinction of 37.5 ± 2.5% (n = 20, selection with 0.5 mg/ml hygromycin B). When cells were selected with 4 mg/ml hygromycin B, maximal extinction was 47.5 ± 3% (n = 10, not shown). Quantification of fluorescence extinction thus allows to determine the fraction of receptors occupied and as a consequence the effective ligand concentration at the membrane. For instance, for the cell shown in Fig. 4, the first ligand application (2 μM, during 1 s) leads a 25% decrease of fluorescence, thus to about 66% occupancy of receptor sites. From the NKA-Bo saturation curve (Fig. 3B), the effective ligand concentration at receptors can be estimated to be about 10 nM. After application, NKA-Bo dissociates from its binding sites at a rate (k off = 0.016 s⁻¹) almost identical to that determined on cell suspensions (k off = 0.018 s⁻¹, not shown). The second application (40-s pulse) results in 37% extinction of fluorescence and reflects saturation of receptor sites.

Calcium responses were also recorded in parallel to ligand binding. A first local NKA-Bo application (1 μM, 5 s) to the cell shown in Fig. 5A leads to a large calcium response. Ligand binding analysis reveals that the receptor fluorescence in the area facing the tip of the application pipette (“east” side of the cell) rapidly decreases by 15.5% (i.e. 40% of receptor sites are occupied). A second application (1 μM, 5 s) of NKA-Bo to the same location, 4.5 min after the first application, does not lead to any detectable calcium response, although more than 50% of receptor sites was not occupied during the first application. Such ligand application to a given pole of a cell followed by a second application to the same pole never led (n = 20) to a second calcium response.

Two approaches were used to test whether calcium release machinery was desensitized or whether receptors were no longer able to couple to intracellular effectors. First, NKA 4–10, a truncated, non-desensitizing version of NKA, was utilized. Successive applications of NKA 4–10 to NK2R expressing oocytes have been shown to trigger repetitive responses (19), whereas NKA only led to a single response. Here, in agreement, repeated applications of NKA 4–10 (10 μM, 5 s) to HEK cells expressing chimera 1 lead to repetitive intracellular calcium elevations (Fig. 5B, n = 5) unlike NKA (10 μM), which never activated a second response (not shown). Second, to further investigate the relationship between receptor site occupancy by NKA-Bo and development of calcium responses, the duration of perfusion pulses was reduced to 3 s to favor local application at one pole of the cell only. Under such conditions, intracellular calcium elevation initiates from limited ligand binding (27% occupancy) to the north pole without detectable receptor occupancy at the south pole (Fig. 6A–C). A second short application (3 s) carried out 6 min later at the same pole resulted in no or a negligibly small response. However, application of ligand to the south pole of the same cell (Fig. 6, D–F) leads to a calcium response resulting from ligand binding to 30% of the south pole.
responses mediated by NK2 neurokinin receptors have not yet been firmly shown to be regulated by G protein receptor kinases, although indirect evidence supports this view (19). NK2 receptors are on the other hand well known to be regulated via desensitization involving activation of protein kinase C by the second messengers calcium and diacylglycerol, produced via desensitization involving activation of protein kinase C by phospholipase C (9, 21). When HEK cells expressing NK2 receptors with no detectable binding at the north pole. Further stimulation of the cell, with either short (0.5 s, not shown) or long (90 s) application to the same pole (Fig. 6, D–F), leads to further receptor occupancy up to saturation (fluorescence decrease at south pole: 35%, corresponding to 95% receptor occupancy) but with significantly reduced or undetectable calcium responses (n = 7) even after several minutes of delay between applications. Taken together, these data demonstrate that the inability of cells to respond to a second NKA-Bo application 4–6 min after the first application is not because of desensitization of the calcium release machinery but rather that it is because of exposure of receptor sites to agonist and thus presumably to homologous and/or heterologous desensitization.

In contrast to NK1 receptors (20), NK2 receptors have not yet been firmly shown to be regulated by G protein receptor kinases, although indirect evidence supports this view (19). NK2 receptors are on the other hand well known to be regulated via desensitization involving activation of protein kinase C by the second messengers calcium and diacylglycerol, produced via phospholipase C (9, 21). When HEK cells expressing WT NK2 receptors are transfected with PKCα-EGFP, application of NKA stimulates PKCα translocation to the plasma membrane (Fig. 7A) and intracellular calcium elevation (Fig. 7B). Local agonist application leads to rapid and reversible PKC translocation to the plasma membrane (as seen in Fig. 7A, recording area 4). Analysis of the time course of PKC translocation (Fig. 7C) reveals that PKC rapidly but transiently migrates to the whole perimeter of the cell (areas 2–4). It then redistributes to a longer lasting membrane-bound form that accumulates at the pole exposed to agonist (Fig. 7A, area 4) with a return to initial conditions within 1 min following agonist application (Fig. 7C).

**DISCUSSION**

Since the identification of G protein-coupled neurotransmitter receptors, many proteins involved in the regulation of the responses mediated by these receptors have been identified and their biochemical roles characterized (4, 7). It is now also well established that stimulation of one defined receptor isotype may trigger several response pathways, depending for instance on the agonist (22), on the cell type (21, 23), on the dose or duration of agonist application (24, 25), or on sequential interaction with intracellular effectors (26). Although several experimental approaches have been developed to better understand, in a dynamic manner, the relationships between the receptors, their ligands, and their effectors (27–31), new tools are still needed to improve detection sensitivity, temporal resolution, and to allow investigation on intact cells.

The recent isolation (32), identification, structural resolution (33, 34), and engineering of the gene encoding jellyfish autofluorescent proteins (35), the green fluorescent protein, and its mutants, has led to the development of new tools to label proteins and to investigate their expression (36), trafficking (37), subcellular distribution (38), homophilic or heterophilic interactions (39), or to monitor structural or conformational changes (40).

As a step toward developing sensitive detection methods applicable to G protein-coupled neurotransmitter receptors, we
Responses Mediated by NK2 Neurokinin Receptors

use EGFP to genetically label the NK2 receptor in a quantitative and homogeneous manner. EGFP was linked to the amino-terminal end of the NK2 receptor, rather than to the carboxyl terminus, for two reasons. First, green fluorescent protein is a substrate of cAMP-dependent protein kinases in mammalian cells (41), and phosphorylation of green fluorescent protein is accompanied by a two-fold increase of fluorescence emission. Because NK2 receptors may stimulate cAMP production, as shown in Rat-1 cells (21), a phosphorylation-associated change in intrinsic green fluorescent protein fluorescence may interfere with the recording of the desired ligand-receptor interaction signal. Second, the calculated Ro value (in the 50 Å range) for energy transfer between EGFP and the Bodipy group indicates that energy transfer can reasonably be measured between fluorophores located on the same side of the plasma membrane. However, it is unlikely, given the size of EGFP (50 × 30 Å) and thickness of the lipid bilayer (40–60 Å), that efficient energy transfer will take place from one side of the bilayer to the other.

We find that fusion of EGFP at the amino-terminal end of the NK2 receptor is an efficient way to label the receptor without altering its properties. Indeed, the expression level of chimera 1 is similar to that of wild type receptors, and confocal micrographs confirm that the fluorescent protein is correctly targeted to the plasma membrane compartment. Also, agonist- and antagonist-binding properties, as well as coupling of the mutant receptor to intracellular calcium responses and long-term regulation of response desensitization, are comparable, if not identical, to those of the wild type receptor. Such absence of changes in the pharmacological and physiological properties of receptors may be general, as similar tagging of the human muscarinic M1 receptor has been also found to yield a fully functional membrane-bound protein (42, 43).

Neither EGFP nor Bodipy appear to behave as conformation-sensitive probes in the present context. Indeed, activation of chimera 1 with NKA is not accompanied by EGFP fluorescence changes, and activation of WT receptor with NKA-Bo also does not result in any fluorescence change of the Bodipy group. Thus, EGFP and Bodipy are likely to freely reorientate, without experiencing changes in their environment, in the unbound and bound forms of the receptor and the ligand, and serve as conformation-independent reporters of receptor-ligand interactions.

NKA-Bo binding is best detected and quantified by measuring extinction of EGFP emission, because at the Bodipy emission wavelength, a significant emission resulting from direct excitation of Bodipy at 460–470 nm is detected. Interestingly, for saturating ligand concentrations, EGFP fluorescence extinction reaches a maximal amplitude that is reproducible between cell batches (37% for cells selected with 0.5 mg/ml hygromycin B and 47% at 4 mg/ml). Thus, as for cell suspensions, effective ligand concentration at the membrane and receptor occupancy can be quantified on single cells. As shown here, direct detection of receptor occupancy allows the estimation of ligand diffusion and thus exposure of receptors to the effective ligand concentration with high spatial resolution.

As previously shown with NKA (19), NKA-Bo leads to rapid and long-lasting desensitization of cellular responses, which contrasts with the nondesensitizing responses elicited by the truncated neurokinin, NKA 4–10. Desensitization of NKA-Bo responses is pronounced at membrane areas exposed to agonist and takes place at concentrations that do not saturate receptor sites. Homologous desensitization, i.e. desensitization of receptor molecules activated by agonist, thus may not represent the sole regulatory pathway accounting for the profound desensitization to NKA-Bo.

NK2 receptors are well known to be regulated via desensitization involving protein kinase C (21). The present work shows that PKC translocation to the membrane is more pronounced and lasts much longer at the pole of the cell exposed to NKA-Bo than at the other poles. This is in agreement with observations made on the tumor mast cell line 2H3 showing that calcium elevation is sufficient to promote PKC translocation to the membrane but not activation, which requires the additional presence of diacylglycerol (9, 44). The present data further suggest that the long lasting translocation of PKC to the plasma membrane takes place in the vicinity of activated receptor molecules, where phospholipase C may selectively become active to locally produce diacylglycerol.

Consistent with the notion of subcellular compartmentalization of G protein-coupled receptor signal transduction regulation is the finding that several effectors of G protein-coupled receptors are localized to membrane microdomains (45–47), where receptor molecules (48–50) associate with heterotrimetric G proteins (51, 52), PKC isoforms (53, 54), and second messengers such as diacylglycerol (55). In such a scheme, compartmentalized desensitization of tachykinin receptors may take place in a pseudo-heterologous manner within membrane microdomains to which active PKC would be targeted and would phosphorylate not only agonist-bound forms of receptors but also unliganded receptor molecules. Therefore, similar to response activation and homologous desensitization, which both strictly depend on exposure to agonist and exhibit com-

![Image](https://example.com/image.png)
partamentalization, heterologous desensitization could also develop in the vicinity of activated receptors.

In conclusion, the present work shows that receptor-ligand interactions at G protein-coupled receptors can be monitored and quantified by fluorescence resonance energy transfer, an approach that is compatible with live cells, and thus with preservation of intracellular effectors of the response and associated second messengers. Such interactions can be measured with high spatial resolution and followed in parallel with intracellular calcium response onset and decline to show compartmentalization not only of response activation but also of intracellular calcium response onset and decline to show compartmentalization, heterologous desensitization could also develop in the vicinity of activated receptors.

Acknowledgments—We thank F. Pattus, M.P. Reck, D. Bertrand, C. D. Muller, and T. Palanché for helpful comments, J. P. Loeffler for the regulating cellular responses mediated by G protein-coupled receptors, and J. Oubert for plasmids.

REFERENCES

1. Changeux, J. P., Devillers-Thiéry, A., and Chemouilli, P. (1984) Science 225, 1335–1345.
2. Karlin, A. (1993) Curr. Opin. Neurobiol. 3, 299–309.
3. Galzi, J. L., and Changeux, J. P. (1994) Curr. Opin. Struct. Biol. 4, 554–565.
4. Lefkowitz, R. J. (1996) Nature Biotechnol. 14, 283–286.
5. Barak, L. S., Ferguson, S. S. G., Zhang, J., and Caron, M. (1997) J. Biol. Chem. 272, 27497–27500.
6. Gilmam, A. G. (1987) Annu. Rev. Biochem. 56, 615–649.
7. Gudermann, T., Schoneberg, T., and Schultz, G. (1997) Annu. Rev. Neurosci. 20, 399–427.
8. Tsunoda, S., Sierrasla, J., Sun, Y., Bodner, R., Suzuki, E., Becker, A., Socolich, M., and Zucker, C. S. (1997) Nature 388, 243–249.
9. Oancea, E., and Meyer, T. (1998) Cell 95, 307–318.
10. Cao, Y. Q., Mantyh, P. W., Carlson, E. J., Gillespie, A. M., Epstein, C. J., and Zuker, C. S. (1997) Neuron 21, 58–66.
11. De Felipe, C., Herrero, J. F. O'Brien, J. A., Palmer, J. A., Doyle, C. A., Smith, A. J. H., Laird, J. M. A., Belmonte, C., Cervero, F., and Hunt, S. P. (1998) Nature 392, 380–384.
12. Nakanishi, S., Nakajima, Y., and Yokota, Y. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 433–437.
13. Schwartz, T. (1994) J. Biol. Chem. 269, 22654–22658.
14. Huaea, R. R. C., Vario, P. P., Strader, C. D., and Fong, T. M. (1995) Biochemistry 34, 10048–10055.
15. Li, Y.-M., Marnerakis, M., Stimson, E. R., and Maggio, J. E. (1995) J. Biol. Chem. 270, 1213–1220.
16. Boyd, N. D., Kage, R., Dumas, J. J., Krause, J. E., and Leeman, S. E. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 843–847.
17. Schwartz, T. (1994) Curr. Opin. Biotechnol. 5, 434–444.
18. Courtier, S., Bertrand, D., Matter, J. M., Hernandez, M. C., Bertrand, S., Millar, N., Valera, S., Barkas, T., and Ballivet, M. (1990) Neuron 5, 845–856.
19. Nemeth, K., and Chollet, A. (1995) J. Biol. Chem. 270, 27601–27605.
20. McConalogue, K., Corvera, C. U., Gamp, P. D., Grady, E. F., and Bunnett, N. W. (1998) Mol. Cell Biol. 9, 2305–2324.
21. Alblas, J., van Etten, H., Khanum, A., and Moolenaar, W. H. (1995) J. Biol. Chem. 270, 8941–8951.
22. Varrault, A., and Boeckel, J. (1992) Naunyn-Schmiedeberg's Arch. Pharmacol. 346, 367–374.
23. Alblas, J., van Etten, H., and Moolenaar, W. H. (1996) EMBO J. 15, 3351–3360.
24. Di Marzo, V., Vial, D., Sokoloff, P., Schwartz, J. C., and Piomelli, D. (1993) J. Neurosci. 13, 4846–4853.
25. Daaka, Y., Luttrell, L. M., and Lefkowitz, R. J. (1997) Nature 390, 88–91.
26. Luttrell, L. M., Ferguson, S. S. D., Daaka, Y., Miller, W. E., Maudealez, S., Della Rocca, G. J., Lin, F., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999) Science 283, 655–661.
27. Breer, H., Boekhoff, I., and Tareilus, E. (1990) Nature 345, 65–68.
28. Fay, S. P., Posner, R. G., Swann, W. N., and Sklar, L. A. (1991) Biochemistry 30, 5666–5675.
29. Varrault, A., and Bockaert, J. (1992) Curr. Opin. Neurobiol. 2, 274–279.
30. Alblas, J., van Etten, H., Khanum, A., and Moolenaar, W. H. (1995) J. Biol. Chem. 270, 27601–27605.
31. McConalogue, K., Corvera, C. U., Gamp, P. D., Grady, E. F., and Bunnett, N. W. (1998) Mol. Cell Biol. 9, 2305–2324.
32. Alblas, J., van Etten, H., Khanum, A., and Moolenaar, W. H. (1995) J. Biol. Chem. 270, 8941–8951.
33. Varrault, A., and Boeckel, J. (1992) Naunyn-Schmiedeberg's Arch. Pharmacl. 346, 367–374.